Abeona Therapeutics Inc. (ABEO) Research
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
Market snapshot
- Symbol
- ABEO
- Price
- $5.77
- Day change
- +2.12%
- Market cap
- $328.9M
- P/E ratio
- 4.94x
- 52-week range
- 4-7.54
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $17.00
Recent news
- Abeona Reports Strong Q1 Revenue, Expands Treatment Center Network
Abeona Therapeutics Inc. (NASDAQ:ABEO) reported first-quarter earnings Wednesday before the market opened. Here's a rundown of the report.
Peer companies
Recent insider activity
- Vasanthavada Madhav — J-Other (222 shares) on 2026-06-16
- Silverstein Christine Berni — S-Sale (18160 shares) on 2026-06-15
- O'Malley Brendan M. — S-Sale (4826 shares) on 2026-06-08
- O'Malley Brendan M. — S-Sale (6305 shares) on 2026-06-09
- Vazzano Joseph Walter — S-Sale (10271 shares) on 2026-06-08
Open Abeona Therapeutics Inc. (ABEO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.